Business Context and Reporting Period
This Form 10-Q covers Gilead Sciences, Inc. for the three-month period ended March 31, 1998. Gilead is a biopharmaceutical company focused on research and development, with its primary commercial product being VISTIDE (cidofovir injection) for the treatment of CMV retinitis in AIDS patients. The company expects to incur losses in 1998 and 1999 due to significant R&D expenditures.
Key Financial Metrics
| Metric | Q1 1998 | Q1 1997 |
|---|---|---|
| Total Revenues | $13.6 million | $5.5 million |
| Net Loss | $(7.4) million | $(7.9) million |
| Loss Per Share (Basic/Diluted) | $(0.25) | $(0.27) |
| Net Cash from Operating Activities | $(6.8) million | $2.5 million |
| Cash and Cash Equivalents (End of Period) | $34.3 million | $104.7 million |
| Short-term Investments | $281.1 million | $N/A (Not listed in 1997 balance sheet) |
| Total Liquid Assets (Cash + Short-term Inv) | $315.4 million | $N/A |
| Accumulated Deficit | $(169.9) million | $(162.5) million |
| Long-term Debt (Non-current) | $1.1 million | $1.3 million |
Material Changes vs. Prior Period
- Revenue Growth: Total revenues increased 148% to $13.6 million, driven primarily by a surge in contract revenues to $11.4 million (up from $2.3 million). This increase was largely due to a $10.7 million reimbursement from F. Hoffmann-La Roche Ltd. for R&D expenses related to GS 4104, including $5.2 million for expenses incurred in late 1997.
- Product Sales Decline: Net product sales from VISTIDE decreased to $1.8 million from $3.0 million, attributed to a decline in CMV retinitis incidence due to improved HIV therapies.
- R&D Expense Surge: Research and development expenses rose 75% to $18.9 million, reflecting the advancement of four therapeutic candidates into later clinical stages.
- Operating Cash Flow: Operating cash flow turned negative at $(6.8) million compared to positive $2.5 million in the prior year, primarily due to the timing of the net loss and changes in working capital.
Outlook, Risks, and Management Commentary
- Profitability Outlook: Management expects to continue incurring losses in 1998 and 1999. R&D and SG&A expenses are projected to increase significantly throughout 1998 to support clinical trials and the potential launch of PREVEON (an investigational HIV drug).
- Liquidity: The company holds approximately $315.4 million in cash and short-term investments. Management believes these resources, supplemented by revenues, are adequate for the foreseeable future, though future funding may be required via equity, debt, or collaborations.
- Risks: Key risks include the failure of product candidates in clinical trials, regulatory approval delays, manufacturing challenges, and intense competition. The company also notes the Year 2000 issue, estimating that system upgrades will not significantly impact operations.
- Unusual Items: The significant increase in contract revenue is non-recurring in nature, tied to specific reimbursement approvals from Roche.
Investor Verification Checklist
- Verify the sustainability of the $10.7 million Roche contract revenue and the likelihood of future reimbursements.
- Monitor the progress and results of the four therapeutic drug candidates currently in later-stage clinical development.
- Assess the declining trend in VISTIDE sales and the potential market size for PREVEON upon launch.
- Review the company's burn rate given the projected increase in R&D and SG&A expenses for the remainder of 1998.
- Confirm the status of Year 2000 compliance for critical third-party supplier systems.